Md. company to study cancer medicine feasibility

 
No Author Published: December 27, 2012    Comment on this article Leave a comment

ROCKVILLE, Md. (AP) — A Rockville company will study the feasibility of a new cancer medicine with the large pharmaceutical company AstraZeneca.


Advertisement

CytImmune Sciences Inc. and AstraZeneca made the announcement on Thursday.

The two companies will work together to see whether they can transmit cancer drugs on extremely small gold particles.

CytImmune works in developing nanomedicine, which uses tiny particles of gold to carry cancer therapies directly to the site of the disease. The company says gold nanoparticles have been used safely since the 1930s to treat patients with rheumatoid arthritis.

Dr. Lawrence Tamarkin, CytImmune's CEO, says the partnership aims to combine CytImmune's nanotechnology research with AstraZeneca's oncology compound to create a cancer therapy that may be widely applicable to solid tumors.





If you prefer your thoughts to appear in The Oklahoman's Opinion section, we encourage you to submit a letter to the editor.


New Rule in ILLINOIS:
(MAY 2013): If You Pay For Car Insurance You Better Read This...
www.ConsumerFinanceDaily.com
Raspberry Pill Melts Fat?
Celebrity Doctor Exposes One Weird Fruit That Melts Your Fat Fast...
PureRaspberryKetone.com

News Photo Galleriesview all